Intrinsic value of Cellectis ADR - CLLS

Previous Close

$25.74

  Intrinsic Value

$2.82

stock screener

  Rating & Target

str. sell

-89%

Previous close

$25.74

 
Intrinsic value

$2.82

 
Up/down potential

-89%

 
Rating

str. sell

We calculate the intrinsic value of CLLS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.9

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  41
  42
  43
  45
  46
  47
  49
  51
  53
  55
  57
  59
  62
  64
  67
  70
  73
  76
  80
  83
  87
  91
  96
  100
  105
  110
  115
  121
  127
  133
Variable operating expenses, $m
  91
  93
  95
  98
  101
  104
  108
  112
  116
  120
  125
  130
  135
  141
  147
  153
  160
  167
  175
  183
  192
  201
  210
  220
  230
  241
  253
  265
  278
  292
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  91
  93
  95
  98
  101
  104
  108
  112
  116
  120
  125
  130
  135
  141
  147
  153
  160
  167
  175
  183
  192
  201
  210
  220
  230
  241
  253
  265
  278
  292
Operating income, $m
  -50
  -51
  -52
  -53
  -55
  -57
  -59
  -61
  -63
  -65
  -68
  -71
  -74
  -77
  -80
  -84
  -87
  -91
  -95
  -100
  -104
  -109
  -114
  -120
  -125
  -131
  -138
  -144
  -151
  -159
EBITDA, $m
  -46
  -48
  -49
  -50
  -52
  -53
  -55
  -57
  -59
  -61
  -64
  -67
  -69
  -72
  -75
  -79
  -82
  -86
  -90
  -94
  -98
  -103
  -108
  -113
  -118
  -124
  -130
  -136
  -143
  -149
Interest expense (income), $m
  0
  1
  41
  72
  107
  147
  191
  240
  292
  349
  411
  476
  547
  622
  702
  787
  878
  974
  1,075
  1,182
  1,295
  1,415
  1,541
  1,674
  1,814
  1,962
  2,118
  2,281
  2,454
  2,635
  2,826
Earnings before tax, $m
  -50
  -92
  -124
  -161
  -202
  -248
  -298
  -353
  -412
  -476
  -544
  -618
  -696
  -779
  -867
  -961
  -1,061
  -1,166
  -1,277
  -1,395
  -1,519
  -1,650
  -1,788
  -1,934
  -2,087
  -2,249
  -2,419
  -2,598
  -2,787
  -2,985
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -50
  -92
  -124
  -161
  -202
  -248
  -298
  -353
  -412
  -476
  -544
  -618
  -696
  -779
  -867
  -961
  -1,061
  -1,166
  -1,277
  -1,395
  -1,519
  -1,650
  -1,788
  -1,934
  -2,087
  -2,249
  -2,419
  -2,598
  -2,787
  -2,985

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  98
  101
  103
  106
  109
  113
  117
  121
  125
  130
  135
  141
  147
  153
  159
  166
  174
  182
  190
  199
  208
  217
  228
  238
  250
  262
  274
  288
  301
  316
Adjusted assets (=assets-cash), $m
  98
  101
  103
  106
  109
  113
  117
  121
  125
  130
  135
  141
  147
  153
  159
  166
  174
  182
  190
  199
  208
  217
  228
  238
  250
  262
  274
  288
  301
  316
Revenue / Adjusted assets
  0.418
  0.416
  0.417
  0.425
  0.422
  0.416
  0.419
  0.421
  0.424
  0.423
  0.422
  0.418
  0.422
  0.418
  0.421
  0.422
  0.420
  0.418
  0.421
  0.417
  0.418
  0.419
  0.421
  0.420
  0.420
  0.420
  0.420
  0.420
  0.422
  0.421
Average production assets, $m
  14
  15
  15
  16
  16
  17
  17
  18
  18
  19
  20
  21
  22
  22
  23
  24
  26
  27
  28
  29
  31
  32
  33
  35
  37
  38
  40
  42
  44
  46
Working capital, $m
  -21
  -22
  -22
  -23
  -24
  -25
  -25
  -26
  -27
  -28
  -29
  -31
  -32
  -33
  -35
  -36
  -38
  -39
  -41
  -43
  -45
  -47
  -50
  -52
  -54
  -57
  -60
  -63
  -66
  -69
Total debt, $m
  2
  3
  5
  6
  8
  10
  13
  15
  18
  21
  24
  27
  30
  34
  38
  42
  46
  51
  56
  61
  66
  72
  78
  85
  91
  98
  106
  114
  122
  130
Total liabilities, $m
  58
  59
  61
  63
  65
  67
  69
  71
  74
  77
  80
  83
  87
  90
  94
  98
  103
  107
  112
  117
  123
  128
  135
  141
  148
  155
  162
  170
  178
  187
Total equity, $m
  40
  41
  42
  43
  45
  46
  48
  49
  51
  53
  55
  58
  60
  62
  65
  68
  71
  74
  78
  81
  85
  89
  93
  98
  102
  107
  112
  118
  123
  129
Total liabilities and equity, $m
  98
  100
  103
  106
  110
  113
  117
  120
  125
  130
  135
  141
  147
  152
  159
  166
  174
  181
  190
  198
  208
  217
  228
  239
  250
  262
  274
  288
  301
  316
Debt-to-equity ratio
  0.040
  0.080
  0.110
  0.150
  0.180
  0.220
  0.260
  0.300
  0.350
  0.390
  0.430
  0.470
  0.510
  0.540
  0.580
  0.620
  0.650
  0.690
  0.720
  0.750
  0.780
  0.810
  0.840
  0.870
  0.890
  0.920
  0.940
  0.970
  0.990
  1.010
Adjusted equity ratio
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409
  0.409

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -50
  -92
  -124
  -161
  -202
  -248
  -298
  -353
  -412
  -476
  -544
  -618
  -696
  -779
  -867
  -961
  -1,061
  -1,166
  -1,277
  -1,395
  -1,519
  -1,650
  -1,788
  -1,934
  -2,087
  -2,249
  -2,419
  -2,598
  -2,787
  -2,985
Depreciation, amort., depletion, $m
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
  8
  8
  8
  9
  9
Funds from operations, $m
  -47
  -88
  -121
  -157
  -199
  -244
  -295
  -349
  -408
  -472
  -540
  -614
  -691
  -775
  -863
  -956
  -1,056
  -1,161
  -1,272
  -1,389
  -1,513
  -1,644
  -1,782
  -1,927
  -2,080
  -2,241
  -2,411
  -2,590
  -2,778
  -2,976
Change in working capital, $m
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
Cash from operations, $m
  -47
  -88
  -120
  -157
  -198
  -244
  -294
  -348
  -407
  -471
  -539
  -612
  -690
  -773
  -861
  -955
  -1,054
  -1,159
  -1,270
  -1,387
  -1,511
  -1,642
  -1,779
  -1,925
  -2,078
  -2,239
  -2,408
  -2,587
  -2,775
  -2,972
Maintenance CAPEX, $m
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
  -7
  -8
  -8
  -8
  -9
New CAPEX, $m
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
Cash from investing activities, $m
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
  -7
  -8
  -9
  -9
  -9
  -10
  -10
  -10
  -11
Free cash flow, $m
  -50
  -91
  -123
  -160
  -202
  -247
  -298
  -352
  -412
  -475
  -544
  -617
  -695
  -778
  -867
  -961
  -1,060
  -1,165
  -1,276
  -1,394
  -1,518
  -1,649
  -1,787
  -1,933
  -2,086
  -2,248
  -2,418
  -2,597
  -2,785
  -2,984
Issuance/(repayment) of debt, $m
  2
  1
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  4
  4
  4
  4
  5
  5
  5
  5
  6
  6
  6
  7
  7
  7
  8
  8
  9
Issuance/(repurchase) of shares, $m
  52
  92
  125
  162
  203
  249
  300
  355
  414
  478
  546
  620
  698
  782
  870
  964
  1,064
  1,169
  1,281
  1,398
  1,523
  1,654
  1,792
  1,938
  2,092
  2,254
  2,424
  2,604
  2,792
  2,991
Cash from financing (excl. dividends), $m  
  54
  93
  127
  164
  205
  251
  302
  357
  417
  481
  549
  623
  701
  786
  874
  968
  1,068
  1,174
  1,286
  1,403
  1,528
  1,660
  1,798
  1,944
  2,099
  2,261
  2,431
  2,612
  2,800
  3,000
Total cash flow (excl. dividends), $m
  3
  3
  3
  3
  4
  4
  4
  5
  5
  5
  6
  6
  6
  7
  7
  8
  8
  9
  9
  10
  10
  11
  11
  12
  12
  13
  14
  15
  15
  16
Retained Cash Flow (-), $m
  -52
  -92
  -125
  -162
  -203
  -249
  -300
  -355
  -414
  -478
  -546
  -620
  -698
  -782
  -870
  -964
  -1,064
  -1,169
  -1,281
  -1,398
  -1,523
  -1,654
  -1,792
  -1,938
  -2,092
  -2,254
  -2,424
  -2,604
  -2,792
  -2,991
Prev. year cash balance distribution, $m
  304
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  256
  -90
  -122
  -159
  -200
  -245
  -295
  -350
  -409
  -473
  -541
  -614
  -692
  -775
  -863
  -956
  -1,056
  -1,161
  -1,272
  -1,389
  -1,513
  -1,643
  -1,781
  -1,926
  -2,080
  -2,241
  -2,410
  -2,589
  -2,777
  -2,975
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  245
  -82
  -106
  -131
  -155
  -178
  -200
  -219
  -235
  -248
  -257
  -262
  -263
  -260
  -253
  -243
  -230
  -214
  -196
  -176
  -156
  -136
  -117
  -98
  -81
  -65
  -52
  -40
  -30
  -22
Current shareholders' claim on cash, %
  67.0
  36.2
  17.0
  7.0
  2.6
  0.8
  0.2
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

FINANCIAL RATIOS  of  Cellectis ADR (CLLS)

Valuation Ratios
P/E Ratio 0
Price to Sales 0
Price to Book 0
Price to Tangible Book
Price to Cash Flow 0
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate -10%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 1175%
Cap. Spend. - 3 Yr. Gr. Rate 119.5%
Financial Strength
Quick Ratio 154
Current Ratio 0.2
LT Debt to Equity 0%
Total Debt to Equity 0.7%
Interest Coverage 0
Management Effectiveness
Return On Assets -18%
Ret/ On Assets - 3 Yr. Avg. -8.9%
Return On Total Capital -22.5%
Ret/ On T. Cap. - 3 Yr. Avg. -11.8%
Return On Equity -22.7%
Return On Equity - 3 Yr. Avg. -11.9%
Asset Turnover 0.2
Profitability Ratios
Gross Margin 31.5%
Gross Margin - 3 Yr. Avg. 52%
EBITDA Margin -114.8%
EBITDA Margin - 3 Yr. Avg. -45.3%
Operating Margin -118.5%
Oper. Margin - 3 Yr. Avg. -61.6%
Pre-Tax Margin -118.5%
Pre-Tax Margin - 3 Yr. Avg. -48.8%
Net Profit Margin -118.5%
Net Profit Margin - 3 Yr. Avg. -51.7%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CLLS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CLLS stock intrinsic value calculation we used $40.4741896759 million for the last fiscal year's total revenue generated by Cellectis ADR. The default revenue input number comes from 0001 income statement of Cellectis ADR. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CLLS stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CLLS is calculated based on our internal credit rating of Cellectis ADR, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Cellectis ADR.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CLLS stock the variable cost ratio is equal to 220%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for CLLS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 2319.7% for Cellectis ADR.

Corporate tax rate of 27% is the nominal tax rate for Cellectis ADR. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CLLS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CLLS are equal to 35%.

Life of production assets of 3.7 years is the average useful life of capital assets used in Cellectis ADR operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CLLS is equal to -51.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $343.222088836 million for Cellectis ADR - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 35.96 million for Cellectis ADR is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Cellectis ADR at the current share price and the inputted number of shares is $0.9 billion.

RELATED COMPANIES Price Int.Val. Rating
PFE Pfizer 43.52 34.10  hold
CELG Celgene 70.24 340.31  str.buy
AFMD Affimed 3.77 0.15  str.sell
BLUE bluebird bio 120.28 7.95  str.sell
BLCM Bellicum Pharm 4.21 1.25  str.sell
NTLA Intellia Thera 18.26 2.46  str.sell
SGMO Sangamo Therap 10.80 3.03  str.sell

COMPANY NEWS

▶ FDA Grants Cellectis IND Approval for UCART22 in B-ALL   [Jun-04-18 04:30PM  Business Wire]
▶ Calyxt Announces Launch of Proposed Follow-On Offering   [May-15-18 05:50PM  Business Wire]
▶ Cellectis to Present Data at the 2018 ASGCT Annual Meeting   [May-10-18 05:15PM  Business Wire]
▶ Cellectis Reports 1st Quarter 2018 Financial Results   [May-07-18 04:30PM  Business Wire]
▶ Cellectis Announces Closing of Follow-On Offering   [Apr-10-18 04:10PM  Business Wire]
▶ Is Cellectis SA Stock a Buy Now?   [Apr-07-18 08:34AM  Motley Fool]
▶ Cellectis Announces Pricing of Follow-On Offering   [Apr-04-18 08:30PM  Business Wire]
▶ Cellectis Announces Launch of Follow-On Offering   [Apr-03-18 05:45PM  Business Wire]
▶ Pfizer Takes On Gilead, Novartis With New Deal In Cancer Drugs   [04:09PM  Investor's Business Daily]
▶ Cellectis SA.s (NASDAQ:CLLS) Profit Outlook   [08:22AM  Simply Wall St.]
▶ [$$] Crispr gene editing ready for testing in humans   [Mar-05-18 12:00AM  Financial Times]
▶ ETFs with exposure to Cellectis SA : December 26, 2017   [Dec-26-17 11:22AM  Capital Cube]
▶ Company News For Dec 14, 2017   [Dec-14-17 10:28AM  Zacks]
▶ This Biotech Stock Rocketed On Human Trials For New Cancer Drug   [Dec-13-17 04:07PM  Investor's Business Daily]
▶ ETFs with exposure to Cellectis SA : November 15, 2017   [Nov-15-17 11:42AM  Capital Cube]
▶ Cellectis SA to Host Earnings Call   [Nov-14-17 07:00AM  ACCESSWIRE]
▶ ETFs with exposure to Cellectis SA : November 3, 2017   [Nov-03-17 12:03PM  Capital Cube]
▶ ETFs with exposure to Cellectis SA : October 24, 2017   [Oct-24-17 09:36AM  Capital Cube]
▶ ETFs with exposure to Cellectis SA : October 13, 2017   [Oct-13-17 10:38AM  Capital Cube]
▶ Bluebird Bio: So Much for That Gilead Boost   [Oct-02-17 03:56PM  Barrons.com]
▶ Juno Therapeutics Inc (JUNO): 3 Reasons to Be Bullish   [Sep-27-17 06:54AM  InvestorPlace]
▶ Cellectis to Participate in Upcoming Investor Conferences   [Sep-04-17 10:30PM  Business Wire]
▶ Cellectis (CLLS) Catches Eye: Stock Jumps 17%   [Aug-29-17 08:40AM  Zacks]
▶ Biotech stocks surge on Gilead's Kite Pharma acquisition   [Aug-28-17 11:41AM  MarketWatch]
▶ Cellectis Granted Patent for CRISPR Use in T-Cells   [Jul-24-17 04:30PM  Business Wire]
▶ New Strong Buy Stocks for July 20th   [Jul-20-17 10:46AM  Zacks]
▶ Cellectis: Annual General Meeting of June 26, 2017   [Jun-09-17 04:48PM  Business Wire]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.